NBY NovaBay Pharmaceuticals Inc.: Pangali EV/EBITDA

NovaBay Pharmaceuticals focuses on combating eye infections by offering the drug Avenova. Its efficacy against microbes without the risk of resistance makes the product a benchmark for hygiene. Stability of raw material supplies is ensured through the diversification of warehouses and routes within the US. The share price retrospective demonstrates the 0.00 metric, which complements the picture of an ophthalmological ecosystem with closed B2B distribution and high patient loyalty.

This indicator compares the total enterprise value with its operating profit before depreciation and amortization, allowing for a real-time assessment of the revaluation of capital-intensive assets. Analysis of the EV/EBITDA multiple chart helps evaluate the effectiveness of NovaBay Pharmaceuticals (NBY) diversification into the dermatology and ophthalmology segments, determining the extent to which the company's market value is justified by the current returns of its retail and prescription sales.